Avastin (Bevacizumab) in Combination With ABVD for the Treatment of Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Inclusion Criteria:

- 18 years of age or older

- Biopsy proven classical Hodgkin lymphoma. Classical Hodgkin lymphoma includes the
subtypes of nodular sclerosis, mixed cellularity, lymphocyte rich, lymphocyte
depleted, and classical Hodgkin lymphoma unspecified

- Advanced stage (Stage III or IV) disease

- Measurable disease on cross sectional imaging

- ECOG Performance Status 0-2

- Adequate blood counts and organ function

Exclusion Criteria:

- Pregnant or lactating women

- Laboratory Parameters as outlined in the protocol

- LV ejection fraction lower than normal as assessed by echocardiogram or MUGA scan

- DLCO less than 60% as measured by pulmonary function tests

- Prior history of another malignancy (except for non-melanoma skin cancer or in situ
cervical or breast cancer) unless disease free for over one year

- Current or recent (within 4 weeks of the first infusion of this study) participation
in an experimental drug study

- Life expectancy of less than 12 weeks

- Inability to comply with study procedures

- Inability to give informed consent

- Inadequately controlled hypertension

- Any prior history of hypertensive crisis or hypertensive encephalopathy

- NYHA Grade II or greater congestive heart failure

- History of myocardial infarction or unstable angina within 6 months prior to study
enrollment

- History of stroke or transient ischemic attack within 6 months prior to study
enrollment

- Known CNS involvement of Hodgkin lymphoma

- Significant vascular disease

- Symptomatic peripheral vascular disease

- Evidence of bleeding diatheses or coagulopathy

- Use of daily anticoagulant medications including warfarin, heparins, or aspirin
>325mg daily

- Major surgical procedure or significant traumatic injury within 28 days prior to
study enrollment or anticipation of need for major surgical procedure during the
course of the study

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days of study enrollment

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to study enrollment

- Serious, non-healing wound, ulcer, or bone fracture

- Proteinuria at screening

- Known hypersensitivity to any component of bevacizumab

- Pregnant or lactating